Trial · NCT00565812
Results by group624
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 624
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Progression of Joint Space Narrowing | SD-0610 50 Milligram (mg) | -0.101 | Standard Deviation 0.346 | mm/year | |
| Rate of Progression of Joint Space Narrowing | SD-0610 200 mg | -0.125 | Standard Deviation 0.298 | mm/year | |
| Rate of Progression of Joint Space Narrowing | Placebo | -0.109 | Standard Deviation 0.261 | mm/year | |
| Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to (<=) 2 | SD-0610 50 Milligram (mg) | -0.061 | Standard Deviation 0.335 | mm/year | |
| Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to (<=) 2 | SD-0610 200 mg | -0.069 | Standard Deviation 0.254 | mm/year | |
| Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to (<=) 2 | Placebo | -0.075 | Standard Deviation 0.221 | mm/year | |
| Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Equal to (=) 3 | SD-0610 50 Milligram (mg) | -0.133 | Standard Deviation 0.352 | mm/year | |
| Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Equal to (=) 3 | SD-0610 200 mg | -0.162 | Standard Deviation 0.319 | mm/year | |
| Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Equal to (=) 3 | Placebo | -0.136 | Standard Deviation 0.286 | mm/year | |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 50 Milligram (mg) | Baseline (n =481, 482, 481) | 39.07 | Standard Deviation 18.85 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 200 mg | Baseline (n =481, 482, 481) | 37.29 | Standard Deviation 17.98 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | Placebo | Baseline (n =481, 482, 481) | 38.45 | Standard Deviation 18.91 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 50 Milligram (mg) | Change at Month 3 (n =449, 450, 455) | -5.35 | Standard Deviation 14.73 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 200 mg | Change at Month 3 (n =449, 450, 455) | -5.08 | Standard Deviation 13.14 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | Placebo | Change at Month 3 (n =449, 450, 455) | -5.50 | Standard Deviation 13.59 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 50 Milligram (mg) | Change at Month 6 (n =424, 426, 433) | -7.20 | Standard Deviation 15.99 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 200 mg | Change at Month 6 (n =424, 426, 433) | -5.84 | Standard Deviation 15.15 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | Placebo | Change at Month 6 (n =424, 426, 433) | -7.07 | Standard Deviation 15.62 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 50 Milligram (mg) | Change at Month 12 (n =370, 388, 397) | -9.17 | Standard Deviation 18.19 | units on a scale |
| Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24 | SD-0610 200 mg | Change at Month 12 (n =370, 388, 397) | -9.25 | Standard Deviation 15.82 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00565812/results